Botulinum toxin to protect salivary glands during radiation for head and neck cancer
Tests botulinum toxin injections to protect salivary glands before radiotherapy in head and neck cancer.
Key facts
- Who runs it
- Fakultni Nemocnice Kralovske Vinohrady
- Where
- Prague, CzechiaSee the site
- Trial code
- Registry title
- Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 23 Sept 2026
- Expected to end
- 1 May 2029
- Type of study
- Interventional
- Record updated
- 2 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with head and neck squamous cell carcinoma who will have radiotherapy. It tests botulinum toxin type A injected into the salivary glands before radiotherapy to protect salivary gland function.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Head and neck squamous cell carcinoma confirmed by tissue examination, with radiotherapy planned.
- Earlier treatment
- No earlier radiotherapy to the head and neck region.
- Biomarker or test result
- The submandibular salivary glands must work symmetrically on the Tc99m scintigraphy scan done before treatment.
Main reasons for not taking part
- Earlier radiotherapy to the head and neck region
- Known salivary gland disease, such as salivary stones or repeated gland inflammation
- Pregnancy or breastfeeding
- Known allergy to botulinum toxin or a nerve-muscle transmission disorder
- Earlier surgery affecting the major salivary glands (assessed case by case)
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age ≥ 18 years
- Histologically confirmed head and neck squamous cell carcinoma indicated for radiotherapy
- Symmetrical function of submandibular glands on pre-treatment Tc99m scintigraphy
- Signed informed consent
Who cannot take part
- Previous radiotherapy to the head and neck region
- Prior surgery affecting major salivary glands (to be evaluated individually)
- Known salivary gland disease (e.g., sialolithiasis, recurrent sialadenitis)
- Known allergy to botulinum toxin or neuromuscular transmission disorders
- Pregnancy or lactation
Where in Czechia
- Fakultni nemocnice Kralovske VinohradyPrague, CzechiaTaking people
About the trial
What the trial wants to find out
To evaluate whether intraglandular application of botulinum toxin type A prior to radiotherapy preserves salivary gland function.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Prevention of radiation-induced salivary gland damage by botulinum toxin application in patients with head and neck cancers
- Plain-language title
- Botulinum toxin to protect salivary glands during radiation for head and neck cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 June 2026